Overview

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

Status:
NOT_YET_RECRUITING
Trial end date:
2026-02-26
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
Phase:
PHASE1
Details
Lead Sponsor:
Addpharma Inc.